Across TCGA pan-cancer cohorts, RBMY2JP RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RBMY2JP data layer.
The strongest signal is observed in thyroid carcinoma (THCA), where higher RBMY2JP RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RBMY2JP expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUSC show a favorable association.
THCA, HNSC, and ACC are the cancer types where RBMY2JP RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.